Obesity Drug Gold Rush: Lilly’s $10B Quarter Sparks $9B Bidding War
Eli Lilly’s Mounjaro and Zepbound generated over $10 billion in Q3 sales, fueling explosive growth in the obesity drug market. The gold rush has sparked a bidding war between Novo Nordisk and Pfizer for experimental drugmaker Metsera.
